Prothena Corporation plc (PRTA)

Market Cap	2.54B
Revenue (ttm)	57.63M
Net Income (ttm)	-140.87M
Shares Out	53.54M
EPS (ttm)	-2.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220,279
Open	48.21
Previous Close	47.60
Day's Range	46.95 - 48.80
52-Week Range	45.06 - 79.65
Beta	0.39
Analysts	Strong Buy
Price Target	87.00 (+83.35%)
Earnings Date	Nov 2, 2023

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 127
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTA

Analyst Forecast

According to 9 analysts, the average rating for PRTA stock is "Strong Buy." The 12-month stock price forecast is $87.0, which is an increase of 83.35% from the latest price.

Price Target

$87.0

(83.35% upside)

Analyst Consensus: Strong Buy